Asad Haider
Stock Analyst at Goldman Sachs
(4.72)
# 712
Out of 4,712 analysts
129
Total ratings
85.7%
Success rate
28.6%
Average return
Main Sectors:
Stocks Rated by Asad Haider
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BNTX BioNTech SE | Reiterated: Buy | $133 → $127 | $98.13 | +29.42% | 6 | Sep 4, 2026 | |
| JNJ Johnson & Johnson | Reiterated: Buy | $282 | $267.08 | +5.59% | 24 | Aug 25, 2026 | |
| MRK Merck & Co. | Reiterated: Buy | $140 → $160 | $147.53 | +8.45% | 21 | Aug 20, 2026 | |
| LLY Eli Lilly and Company | Reiterated: Buy | $1,283 → $1,367 | $1,124.21 | +21.60% | 24 | Aug 6, 2026 | |
| RPRX Royalty Pharma | Reiterated: Buy | $59 → $66 | $60.59 | +8.93% | 4 | Aug 6, 2026 | |
| PFE Pfizer | Reiterated: Hold | $26 | $27.78 | -6.41% | 20 | Aug 4, 2026 | |
| ABBV AbbVie | Reiterated: Hold | $244 | $250.91 | -2.75% | 8 | Jul 21, 2026 | |
| BMY Bristol-Myers Squibb Company | Reiterated: Hold | $61 | $64.41 | -5.29% | 11 | Jul 20, 2026 | |
| NAMS NewAmsterdam Pharma Company | Reiterated: Hold | $37 → $38 | $22.79 | +66.74% | 4 | May 7, 2026 | |
| INVA Innoviva | Reiterated: Sell | $17 → $18 | $21.13 | -14.81% | 2 | May 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $38 → $67 | $59.51 | +12.59% | 2 | Feb 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $270 | $391.27 | n/a | 1 | Dec 16, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $66 | $10.72 | n/a | 1 | Dec 16, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $168 | $159.51 | n/a | 1 | Dec 14, 2018 |
BioNTech SE
Sep 4, 2026
Reiterated: Buy
Price Target: $133 → $127
Current: $98.13
Upside: +29.42%
Johnson & Johnson
Aug 25, 2026
Reiterated: Buy
Price Target: $282
Current: $267.08
Upside: +5.59%
Merck & Co.
Aug 20, 2026
Reiterated: Buy
Price Target: $140 → $160
Current: $147.53
Upside: +8.45%
Eli Lilly and Company
Aug 6, 2026
Reiterated: Buy
Price Target: $1,283 → $1,367
Current: $1,124.21
Upside: +21.60%
Royalty Pharma
Aug 6, 2026
Reiterated: Buy
Price Target: $59 → $66
Current: $60.59
Upside: +8.93%
Pfizer
Aug 4, 2026
Reiterated: Hold
Price Target: $26
Current: $27.78
Upside: -6.41%
AbbVie
Jul 21, 2026
Reiterated: Hold
Price Target: $244
Current: $250.91
Upside: -2.75%
Bristol-Myers Squibb Company
Jul 20, 2026
Reiterated: Hold
Price Target: $61
Current: $64.41
Upside: -5.29%
NewAmsterdam Pharma Company
May 7, 2026
Reiterated: Hold
Price Target: $37 → $38
Current: $22.79
Upside: +66.74%
Innoviva
May 6, 2026
Reiterated: Sell
Price Target: $17 → $18
Current: $21.13
Upside: -14.81%
Feb 26, 2026
Reiterated: Hold
Price Target: $38 → $67
Current: $59.51
Upside: +12.59%
Dec 16, 2019
Upgraded: Buy
Price Target: $270
Current: $391.27
Upside: n/a
Dec 16, 2019
Upgraded: Buy
Price Target: $66
Current: $10.72
Upside: n/a
Dec 14, 2018
Reiterated: Buy
Price Target: $168
Current: $159.51
Upside: n/a